Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Enzerna
AddedFeb 18, 2024
UpdatedJun 18, 2026
Enzerna

Enzerna

Angel

Enzerna Biosciences, a pre-clinical stage company, uses ASREs to combat nucleotide expansion disorders.

HQ
Morrisville, NC, US
Founded
2013
Overview
Compare
Fundraising
Employees
Website

Enzerna Biosciences, Inc, founded as a pre-clinical stage company, is dedicated to developing gene therapies for rare genetic disorders. Their core mission is to leverage proprietary RNA editing technology to create long-term curative solutions for nucleotide expansion disorders like Myotonic Dystrophy and Huntington’s Disease. Enzerna's primary product involves Artificial Site-Specific RNA Endonucleases (ASREs), designed to target and destroy toxic RNA molecules that cause these genetic diseases.

Notable affiliated individuals and investors include experts in genetic research and biotechnology investment firms, though specific names are not publicly detailed. Key achievements include the development of their innovative ASRE technology, positioning Enzerna as a promising player in the gene therapy market. The overall impact of Enzerna Biosciences lies in its potential to provide groundbreaking treatments for currently incurable genetic disorders, offering hope to patients and advancing the field of genetic medicine.

Enzerna - Similar Companies

Atsena Therapeutics logo

Atsena Therapeutics

atsenatx.com

Locanabio logo

Locanabio

EnPlusOne Biosciences logo

EnPlusOne Biosciences

enplusonebio.com

Airna logo

Airna

airna.com

EnClear Therapies logo

EnClear Therapies

Triplet Therapeutics logo

Triplet Therapeutics

triplettx.com

EnzymeRx logo

EnzymeRx

Cadenza Bio logo

Cadenza Bio

cadenza.bio

Nextrna Therapeutics logo

Nextrna Therapeutics

Acrigen Biosciences logo

Acrigen Biosciences

acrigen.com

Epic-Bio logo

Epic-Bio

epic-bio.com

Escape Bio logo

Escape Bio

escapebio.com

Alltrna logo

Alltrna

alltrna.com

Sarepta Therapeutics logo

Sarepta Therapeutics

sarepta.com

Selonterra logo

Selonterra

selonterra.com

Enzerna - Quick Facts

Who are Enzerna's competitors?

Companies similar to Enzerna include Atsena Therapeutics, Locanabio, EnPlusOne Biosciences and Airna.

When was Enzerna founded?

Enzerna was founded in 2013.

Where is Enzerna's headquarters located?

Enzerna's headquarters is located in Morrisville, NC, US.

When was Enzerna's last funding round?

Enzerna's most recent funding round was for $250k (USD) in November 2022.

How much has Enzerna raised to-date?

As of Nov 9, 2022, Enzerna has raised a total of $250k (USD).

How many employees does Enzerna have?

Enzerna has 9 employees as of Feb 4, 2024.

Enzerna - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Software
Customer
  • Enterprise
Main Product
  • Gene Therapy
Tags
  • Consulting
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 9 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified